Dry powder formulations of dNase I
DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.
1. An inhalable dry powder formulation comprising a human DNase I protein and particles of a physiologically acceptable pharmacologically-inert solid carrier, wherein said human DNase I protein is a plant expressed recombinant human DNase I protein comprising an N-terminal Glycine residue at position 1 of said human DNase I protein.
2. The inhalable pharmaceutical composition of claim 1 , wherein said human DNase I protein comprising an N-terminal Glycine residue at position 1 of said human DNase I protein comprises the amino acid sequence as set forth in SEQ ID NO: 6.
3. The inhalable dry powder formulation of claim 1 , wherein said human DNase I protein comprises the amino acid sequence as set forth in SEQ ID NO:5.
4. The inhalable dry powder formulation of claim 1 , wherein said human DNase I protein has at least one core xylose and at least one core α-(1,3) fucose.
5. The inhalable dry powder formulation of claim 1 , wherein said human DNase I protein has reduced susceptibility to actin inhibition of endonuclease activity as compared with that of mammalian cell expressed human recombinant DNase I.
6. The inhalable dry powder of claim 1 , wherein said carrier is selected from the group consisting of (a) at least one crystalline sugar selected from the group consisting of glucose, arabinose, maltose, saccharose, dextrose, and lactose; and (b) at least one polyalcohol selected from the group consisting of mannitol, maltitol, lactitol, and sorbitol.
7. The inhalable dry powder formulation of claim 1 , wherein said carrier is in a form of finely divided particles having a mass median diameter (MMD) in the range of 0.5 to 10 microns.
8. The inhalable dry powder formulation of claim 1 , wherein said carrier is in a form of coarse particles having a mass diameter of 50-500 microns.
9. The inhalable dry powder formulation of claim 1 , wherein said carrier comprises a mixture of coarse particles having a mass diameter of 150 microns to 400 micron and finely divided particles having a MMD in the range of 0.5-10 microns.
10. The inhalable dry powder formulation of claim 1 , further comprising, as an active ingredient, a magnesium salt.
11. The inhalable dry powder formulation of claim 1 , further comprising, as an active ingredient, an agent for inhibiting formation of G actin and/or enhancing formation of F actin.
12. The inhalable dry powder formulation of claim 1 , wherein said human DNase I is in association with diketopiperazine.
13. The inhalable dry powder formulation of claim 1 , wherein said human DNase I protein is at least 90-95% pure human DNase I protein.
14. The inhalable dry powder formulation of claim 1 , further comprising plant beta-acetylhexosaminidase enzyme protein.
15. The inhalable dry powder formulation of claim 14 , wherein said plant beta-acetylhexosaminidase enzyme protein is inactivated beta-acetylhexosaminidase enzyme protein.
16. A method of reducing DNA in a pulmonary secretion or fluid of a subject in need thereof, the method comprising administering to the subject the inhalable dry powder formulation of claim 1 , thereby reducing DNA in the pulmonary secretion or fluid of the subject.
17. A method of treating a pulmonary disease or condition associated with excess DNA in a pulmonary secretion in a subject in need thereof, the method comprising administering to the subject the inhalable pharmaceutical composition of claim 1 , thereby treating the pulmonary disease or condition associated with excess DNA in the pulmonary secretion in the subject.
18. The method of claim 16 , wherein said subject is suffering from a respiratory disease selected from the group consisting of acute or chronic bronchopulmonary disease, atelectasis due to tracheal or bronchial impaction, and complications of tracheostomy.
19. The method of claim 18 , wherein said acute or chronic bronchopulmonary disease is selected from the group consisting of infectious pneumonia, bronchitis or tracheobronchitis, bronchiectasis, cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), TB or fungal infections.
20. The method of claim 19 , wherein an effective amount of said dry powder formulation is a plurality of doses, each dose comprising 1.0-3.0 mg DNase, said doses administered at least twice, 2-3 times, 2-4 times or 2-6 times daily.